Gruppo Chiesi Acquires New Production Site in Nerviano
Deal News | Apr 09, 2025 | Legal Community Italy
Gruppo Chiesi, an international biopharmaceutical group headquartered in Parma, has acquired a company that owns a production site in Nerviano, Milan. This strategic acquisition is part of Chiesi's global industrial strategy, supported by Gianni & Origoni (Gop), a legal team led by partner Teodora Marocco for environmental issues, managing associate Nicola Zito for M&A, and partner Gianfranco Toscano with associate Mariangela De Cesare for real estate law aspects. The seller, Orofino Pharmaceuticals Group S.r.l, was advised by Chiomenti, with partners Paolo Fedele, Renato Genovese, Marco di Siena, and lawyer Ilaria Secchiatti. The €430 million investment from 2025 to 2030 aims to revitalize the historical site, originally built as an oncology research center by Farmitalia Carlo Erba in 1965, into a sustainable production hub for inhalers with low carbon footprint. The site will also develop sterile biologics and dry powder inhalers, featuring modern laboratories and a photovoltaic park for energy self-sufficiency. This initiative aligns with Gruppo Chiesi's goal of achieving Net Zero emissions by 2035.
Sectors
- Biopharmaceutical
- Real Estate
Geography
- Italy – The acquisition involves a production site in Nerviano, Milan, and the headquarters of Gruppo Chiesi is in Parma, Italy.
- France – Part of the broader strategy of Gruppo Chiesi involves investments in their site in Blois, France.
- Brazil – The strategy also includes activities in Santana de Parnaiba, Brazil, as part of Gruppo Chiesi's global growth plans.
Industry
- Biopharmaceutical – The acquisition targets the biopharmaceutical industry, focusing on the production of therapeutic products such as inhalers and biologics.
- Real Estate – Involves the acquisition of a property to be transformed into a production site, with legal aspects concerning real estate addressed in the deal.
Financials
- 430 million euros – The total investment planned over the period from 2025 to 2030 for the acquisition and transformation of the production site.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Gruppo Chiesi | Buyer | Company | An international biopharmaceutical group headquartered in Parma, Italy. |
| Orofino Pharmaceuticals Group S.r.l | Seller | Company | The company selling the property site to Gruppo Chiesi. |
| Gianni & Origoni (Gop) | Legal Advisor | Company | Law firm that assisted Gruppo Chiesi in the acquisition. |
| Chiomenti | Legal Advisor | Company | Law firm that assisted the vendor, Orofino Pharmaceuticals. |